2023 Wrap Up - SafeBridge Newsletter

2023 Wrap Up - SafeBridge Newsletter

SafeBridge Newsletter

In this Issue:

Upcoming Training / Latest News / Expert Spotlight / Upcoming Conferences


Upcoming?Training

Following are classroom trainings that will occur in the near future. Visit our website for a complete list of trainings and on-demand webinars.

Featured Courses

Classroom Training

SafeBridge? Boot Camp India 2024: Can you handle it safely? Potent Compound Safety Training?*

Feb 2 - 3, 2024 / Hyderabad, India

Feb 5 - 6, 2024 / Mumbai, India

This 2 day course in Pharmaceutical Potent Compound Safety, taught by the leading industry experts in potent compound safety, is designed for EHS and related professionals who need to understand the critical concepts of evaluating and safely handling pharmaceutical compounds.

The intensive curriculum focuses on evaluation of compound potency and toxicity, sampling and monitoring protocols, control technologies and application of qualitative and quantitative approaches.

The training offers NEW and improved content to help you with your potent compound safety issues and to train you on new aspects that have become important that were not in our course when we came to India in 2018, e.g., PDEs, ADCs, new modalities, and more on containment performance testing.

Register


SafeBridge? Potent Compound Safety “Boot Camp” ??*

Feb 27 - 29, 2024 / San Diego, CA

Jun 18 - 20, 2024 / Cambridge, United Kingdom

This three-day course in pharmaceutical potent compound safety is designed for EHS and related professionals who need to understand the critical concepts of evaluating and safely handling pharmaceutical compounds. It is taught by the leading industry experts in potent compound safety, The intensive curriculum focuses on evaluation of compound potency and toxicity, sampling and monitoring protocols, control technologies, and effective investigation and communication approaches. After two days of introductory information, topics will shift to case studies and problem solving to address potent compound safety issues in discovery, development, contract manufacturing, and commercialization. It leverages a systematic approach to successfully support drug R&D and manufacturing operations.

Register


Latest News

Hazardous Drugs in Health Care Settings – ARE YOU COMPLIANT with USP <797>/<800>?

SafeBridge and Working Buildings, both affiliated companies of Trinity Consultants, Inc. attended, presented, and discussed with pharmacists and health care staff at the American Society of Hospital Pharmacies (ASHP) Midyear Conference in Anaheim in December. At our mix and mingle event, we presented on the following topics.

  • Embarking on a 503(b) Pharmacy? What You Need to Know - Kurt Last of Working Buildings
  • Cleanroom Design – Lessons Learned – Elain Strauss and Tony Martin of Working Buildings
  • HD Surface Sampling and Science: Protecting Pharmacists and Healthcare Workers – Kent Rader, Amy Snow and Allan Ader of SafeBridge

Are you and/or your customers ready for your State Pharmacy Board audits of your facilities in the handling of hazardous drugs?

If not or you're unsure, use our combined resources that no other company has from design review of your facility, program review, compliance with the guideline assessment to wipe sampling, analysis and interpretation. The combined resources of SafeBridge and Trinity are the only technical resource consultant that can meet your entire USP <797>/<800> program compliance needs.

For more assistance and information, please contact [email protected].

Read more…


SafeBridge Helps Clients Get Approvals for Their Drugs Requiring Complex Extractable and Leachable (E&L) Testing, Interpretation and Toxicological Assessment

For the second time in the past three years, SafeBridge has been able to assist Clients who have received FDA deficiencies and warnings about their regulatory submission package for dermal patch products overcome these challenges and get marketing approvals for their drug products Not only did we do the toxicological assessments which had been deficient due to improper evaluation of data and poor toxicological risk assessment approaches, e.g., not developing dermal Permitted Daily Exposure (PDE) values, but in our most recent case, helped design, place and interpret studies at laboratories for the E&L studies.

We also continue to support E&L submissions for parenteral and inhalation drug products and for devices to meet regulatory requirements, so we are doing many E&L assessments per year from design of studies to regulatory submissions.

SafeBridge and our subcontractor, Material Needs Consulting, provide the following services in E&L for biotechnology and pharmaceutical product development including the following:

  • Conduct an assessment of appropriate testing conditions based on route of administration, product contact surfaces, drug formulation and other factors.
  • Qualify laboratories for testing.
  • Project management of entire E&L program
  • E&L study protocol review, study management and monitoring
  • Biocompatibility testing protocol review, study management and monitoringUSP <87>, <88>, <661>, <381>, and ISO-10993
  • Quality assurance review of E&L testing results and reports
  • Provide toxicology assessment for patient safety purposes Developing PDEs: For each chemical or class of chemicals above the Analytical Evaluation Threshold (AET), SafeBridge develops a Permitted Daily Exposure (PDE) value. A PDE is a health-based limit and represents a dose (either oral, intravenous (IV), or otherwise specified) that is unlikely to cause an adverse effect if an individual is exposed by that route, at or below this dose every day for a lifetime.Develop a health based risk assessment for patient safety that provides a compelling and robust assessment of the data by toxicologist experience in E&L assessment for submissions to regulatory agencies

For more information, please contact: Mac Taylor, DVM, DABT at [email protected] or [email protected].

Read more…


GRAS isn’t just for Livestock!

In the Food & Beverage world, GRAS is not just something to feed to cows. GRAS is a United States Food and Drug Administration (FDA) designation that a chemical or substance added to food is considered to be ‘generally recognized as safe’ (GRAS) by experts under the conditions of its intended use. Experts in the SafeBridge Tox-Reg group have achieved very high success rates in obtaining GRAS status for food and beverage ingredients. The FDA-GRAS process can be challenging, as the supporting dossier must adequately describe and justify that the new ingredient is safe via a thorough narrative encompassing the substance’s identity and composition, manufacturing process, and summaries of toxicological and human studies related to the safety of the substance for the intended use. An important consideration is assessment of any potential allergenicity of the ingredient. Estimating exposure is a key determining step in the evaluation of a food substance, as the safety is related to total cumulative intake, i.e., proposed new uses plus background dietary exposure. SafeBridge coordinates GRAS panels, a group of experts responsible for evaluating the dossier. If the GRAS panel determines that there is a consensus within the scientific community that the substance is safe for its intended use in food, is manufactured according to current Good Manufacturing Practices (cGMP), and meets appropriate food specifications, the substance may be granted GRAS status. From there, our Clients may decide to submit the GRAS Dossier to the FDA (GRAS Notification) or decide to maintain a Self-Affirmed GRAS.

GRAS is the core of our Food & Beverage offerings – from facilitating the approval for our clients, performing dietary exposure assessments, or serving as experts on GRAS panels coordinated by other consultants. Let us show you our passion for developing client relationships to bring forth meaningful change.

Read more…


More Articles


Expert Spotlight

Matthew Linman

Meet our newest Senior Consultant, Matthew Linman, Ph.D.! Previously, Matt was the Assistant Scientific Director for the Flavor and Extract Manufacturers Association of the United States (FEMA) where he was responsible for managing scientific work focused on flavor safety, the FEMA GRAS (Generally Recognized as Safe) program, the FEMA Science Affairs Committee, scientific manuscripts, and exposure assessments. Before joining FEMA, Matt worked as an engineering scientist at Meso Scale Diagnostics (MSD) developing new instruments along with associated consumables and assays for the next generation of electrochemiluminescence (ECL)-based products. Matt received his B.A. in Chemistry from The College of Wooster and Ph.D. in Analytical Chemistry from the University of California at Riverside where he developed biointerfaces and novel materials for biosensing applications using surface plasmon resonance spectroscopy (SPR) and SPR imaging.

Matt is an avid distance runner (ran cross-country/track in college) and a decent ballroom/Latin dancer. He enjoys spending time with his physicist wife, Kathy, and his daughter, exploring all that the Washington, DC area has to offer. Connect with Matt Linman.

Deirdre Love

Meet Deirdre Love, PhD, MPH, CPH,?one of our Associate Toxicologists!

Deirdre’s passion for science began as an undergraduate at the University of South Carolina, where she earned a bachelor's degree in Public Health. Following graduation, she joined the master's in public health program at the University of Florida. While a master's student, she worked for the USDA on a Department of Defense project to protect deployed soldiers from vector-borne infectious diseases. She then went on to join the PhD program where she focused on aquatic and human health following exposure to pesticides.

In her free time Deirdre enjoys reading, travelling, playing tennis, and being out on the water with her husband.

Connect with Deirdre Love.

Dylan James

Meet Dylan James, our newest Associate Industrial Hygienist!

Dylan is a recent graduate of the University of North Carolina and SafeBridge's most recent TAK Scholarship recipient. Dylan is currently completing his master’s at the Gillings School of Global Public Health in environmental sciences and engineering with a focus on industrial hygiene.

Dylan is passionate about protecting the health of workers. Before starting with SafeBridge, he gained experience in industrial hygiene by interning with Liberty Mutual and Fujifilm Diosynth Biotechnologies. He also spent his undergrad working as a part time industrial ventilation consultant for Air Systems Corporations and is currently an instructor at the North Carolina Industrial Ventilation Conference.

Dylan loves being outside. He regularly enjoys taking trips with friends outdoors to rock climb, ski and mountain bike.

Connect with Dylan James.

Upcoming Conferences

The Toxicology Forum

Jan 22 - 24, 2024 / Pentagon City, VA

Anne Chappelle will be attending. Presentations by Bob Sussman and George (Mac) Taylor.

EHS for BioPharma Summit

Feb 27 - 29, 2024 / Boston, MA

Lillian Fry, Allan Ader and others will be there! Visit us at?our booth.

AIHA Carolinas Spring PDC/Conference

Mar 6 - 8, 2024 / Raleigh, NC

Amy Snow will be presenting SafeBridge. Don’t forget to stop by our booth!

Society of Toxicology Tox Expo (SOT)

Mar 10 - 14, 2024 / Salt Lake City, UT

Stop by Booth #1305?and say hello to the?SafeBridge Tox?team!

Amazing content as always, #SafeBridge team! ?? As Steve Jobs once said, "Innovation distinguishes between a leader and a follower." Your dedication to #healthandsafety and #training in the pharma industry clearly sets you apart as leaders. Keep up the brilliant work! ???? #inspirationalquotes

回复
Anne Chappelle, Ph.D. DABT

Toxicology Board Certified; Regulatory Professional; Expert in Chemical Evaluation and Occupational Risk Assessment

1 年

Our last newsletter of the year!

回复

要查看或添加评论,请登录

Trinity Consultants - SafeBridge的更多文章

社区洞察

其他会员也浏览了